Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Senior Editor

Reynald Castañeda

Deputy Editor

Bayer has shuttered a Phase II program that the EMA had designated an orphan drug “for scientific reasons,” the German conglomerate disclosed in its half …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves

Amber Tong

Senior Editor

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Senior Editor

Deputy Editor

Sign up to read this article for free.

Updated: Bayer cuts PhII orphan drug as it ups R&D spending, questions swirl around new CEO’s next moves